Purun'ao

Beijing Purun'ao Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the development of innovative small molecule therapeutics for oncology and hematology. The company's primary focus is on targeting the PI3K signaling pathway, which plays a critical role in the proliferation and survival of various cancer cells. Its lead asset, PRO-001, is a potent and selective PI3Kδ inhibitor currently undergoing Phase 2 clinical evaluation for the treatment of relapsed or refractory follicular lymphoma and other B-cell malignancies. Purun'ao aims to provide more effective and safer treatment options for patients through its specialized drug discovery platform and clinical development expertise. The company continues to expand its pipeline with candidates targeting diverse mechanisms in the tumor microenvironment.